New hope for rare amyloidosis: targeted drug combo enters trial
NCT ID NCT07224672
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new drug, belantamab mafodotin, combined with standard chemotherapy in 60 adults newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if the combination improves blood and organ responses. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody) combined with cyclophosphamide, bortezomib, and dexamethasone (chemotherapy drugs)
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with newly diagnosed AL amyloidosis, potentially improving organ function and survival.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 60 participants. The drug combination may cause side effects, including eye problems, and may not prove more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••